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Development features and study characteristics of mobile
health apps in the management of chronic conditions: a
systematic review of randomised trials
Maria Cucciniello1,2, Francesco Petracca 2, Oriana Ciani 2,3 and Rosanna Tarricone 2,4✉
COVID-19 pandemic challenges have accelerated the reliance on digital health fuelling the expanded incorporation of mobile
apps into healthcare services, particularly for the management of long-term conditions such as chronic diseases (CDs).
However, the impact of health apps on outcomes for CD remains unclear, potentially owing to both the poor adoption of
formal development standards in the design process and the methodological quality of studies. A systematic search of
randomised trials was performed on Medline, ScienceDirect, the Cochrane Library and Scopus to provide a comprehensive
outlook and review the impact of health apps on CD. We identified 69 studies on diabetes (n= 29), cardiovascular diseases
(n= 13), chronic respiratory diseases (n= 13), cancer (n= 10) or their combinations (n= 4). The apps rarely adopted
developmental factors in the design stage, with only around one-third of studies reporting user or healthcare professional
engagement. Apps differed significantly in content, with a median of eight behaviour change techniques adopted, most
frequently pertaining to the ‘Feedback and monitoring’ (91%) and ‘Shaping knowledge’ (72%) categories. As for the study
methodologies, all studies adopted a traditional randomised control trial (RCT) design, with relatively short follow-ups and
limited sample sizes. Findings were not significant for the majority of studies across all CD, with most RCTs revealing a high risk
of bias. To support the adoption of apps for CD management, this review reinforces the need for more robust development
and appropriate study characteristics to sustain evidence generation and elucidate whether study results reflect the true
benefits of apps or a biased estimate due to unsuitable designs.
npj Digital Medicine           (2021) 4:144 ; https://doi.org/10.1038/s41746-021-00517-1
INTRODUCTION
Smartphone users in the world have steadily increased, surpassing
the 3.5 billion mark in 2020 with a further expected growth of
several hundred million in the coming years1, fuelling the
expanding interest in mHealth apps2. The coronavirus disease
2019 (COVID-19) pandemic has contributed to further accelerate
the reliance on digital health3–5.
Therefore, apps are being increasingly incorporated into
healthcare (HC) services owing to their portability, instantaneous
access and direct communication, inspiring new models of remote
HC delivery and cost-effective solutions for chronic diseases,
whose long-term nature and need for continuous monitoring can
be positively impacted2,6,7. mHealth apps may be particularly
effective in self-management, one of the components of the
eHealth Enhanced Chronic Care Model8, intended as the
‘individual’s ability to manage the symptoms, treatment, physical
and psychosocial consequences and lifestyle changes inherent in
living with a chronic disease’9. Apps could as well improve patient
empowerment, the process of gaining knowledge of one’s health
and ability and motivation to influence it10,11.
Despite the ever-growing interest and the increasing number
of apps on common platforms, their impact on outcomes for
chronic diseases remains unclear. Several systematic reviews
and meta-analyses reported mixed impact of apps on clinical
outcomes, self-management and behaviour change12–21,
questioning the ability of science to keep up with the
continuous technological advances22.
The inconclusive evidence base of apps could be attributed
both to the poor adoption of formal development standards23,24,
notwithstanding the reported benefits of adopting participatory
approaches and behaviour change theories25,26, and to the
methodological quality of study designs27.
Previous reviews had summarised the impact of apps on
health outcomes across different conditions, concluding that
high-quality research is needed to transform the promise of
mHealth technology into improved HC delivery and out-
comes7,28. More recently, Iribarren et al. comprehensively
reviewed app-delivered behaviour change interventions target-
ing health outcomes and thoroughly analysed the correspond-
ing app features29. However, no study on chronic diseases has
comprehensively looked at both the developmental features of
apps, namely the strategies and considerations adopted
throughout the development stage of mobile apps, thereby
including the behavioural change features adopted, and the
characteristics of the evaluation study in determining the effect
on a wide array of domains.
We, therefore, conducted a systematic review of randomised
studies on smartphone apps for the management of high
prevalence diseases (diabetes, cardiovascular diseases, chronic
respiratory diseases and cancer) to fill this gap.
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Following the removal of duplicates, the addition of 16 publica-
tions cited in reference lists, and title and abstract screening, 175
records were selected for full-text examination. The Cohen’s kappa
coefficient expressing the inter-rater agreement was 0.84 during
the abstract screening.
Overall, 74 papers based on 69 different trials were included in
the review. The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) flowchart of the study selection
process is presented as Fig. 1, including the reported reasons for
exclusion.
Characteristics of included studies and participants
The studies were published between 2008 and 2019 in 24
countries, with the United States of America (n= 13)30–43 and
China (n= 7)44–50 ranked first and second, respectively. Only one
study covered multiple countries, involving diabetes clinics in Italy,
England and Spain51.
The chronic disease most commonly addressed was diabetes
(n= 29, 42.0%), with 16 studies sampling type 2 diabetes (T2DM)
population in 19 articles30–33,42,48,49,52–63, 10 focusing on type 1
diabetes (T1DM)51,64–72 and three enrolling both T1DM and T2DM
patients in four articles45,73–75. Thirteen studies (18.8%) targeted
cardiovascular diseases, with five focusing on heart failure35,36,76–78
and the remaining on cardiovascular diseases (CVDs)34,38,39,79–84.
An equal number addressed chronic respiratory diseases (n= 13,
18.8%), with seven studies tackling asthma41,85–90 and six focusing
on chronic obstructive pulmonary disease (COPD)91–96. Lastly, ten
studies focused on cancer (n= 10, 14.5%)40,43,44,46,47,50,97–100. One
study separately addressed T2DM and CVDs (either ischaemic heart
disease or heart failure)101, while two others included both
uncontrolled hypertension and diabetes37,102 and one focused
on T2DM and/or hypertension103. Their sample sizes ranged from
1835 to 519101 and the median size was 94, with 23 studies (33.3%)
totalling between 50 and 100 participants and only six studies with
more than 200 individuals33,39,59,88,90,101.
The vast majority were either individually randomised parallel-
group trials (n= 52, 75.4% of total studies) or pilot RCTs (n= 12,
17.4%), while the remaining five had a cluster-randomised (n= 3,
4.3%)31,37,90 or an individual cross-over design (n= 2, 2.9%)69,72.
Out of the 69 studies, 60 were two-arm, while eight (11.6%) had
three and one (1.4%) had four groups31. Among those with
multiple intervention groups, several studies, along with the
standard app version, included a different arm with an enhanced
intervention, on top of app use, with the possibility of using either
the teleconsultation option64, Health Counselling intervention53,
classroom-based programmes33, decision support31, physician
review100 or additional app features84. Frias et al., instead, had
two intervention arms using the same app, but with different
follow-ups37.
In the control group, most participants received care as usual.
However, some studies included lighter technological features for
the control group: Johnston et al. provided the control with a
simplified drug adherence e-diary installed on phones83, while
other studies either included basic versions of the app68 or
administered education/information programmes over mobile
Fig. 1 Study selection flow diagram. Modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
of the article selection process.
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phones35,43. Ryan et al.88 provided the control with enhanced
clinical care to exclude attribution of potential benefits to intense
interventions in the app group. Franc et al.’s study60, besides the
Diabeo app arm, included a simpler telemonitoring system via an
interactive voice response system, while Kwon et al.93 adopted
two different exercise regimens.
The follow-ups varied: for 26 studies, they were between 4 and
6 months (37.7%); for 24 studies (34.8%), 1–3 months; in 13 cases
(18.8%), >6 months and for the remaining six (8.7%) only 4 weeks.
The majority of the studies (n= 44, 63.8%) included internet
literacy as an explicit eligibility criterion, as either generic
familiarity with mobiles or, more explicitly, ownership of
smartphones with specific operating systems. A notable exception
is Baron et al.’s study73 excluding those with previous mobile
telehealth services experience.
Recruitment procedures were mostly traditional, with offline
methods for 64 studies (92.7%). Only Morawski et al.39 adopted a
completely online recruitment strategy, through patient commu-
nities, social media, mobile apps and advertisement, while four
studies pursued both offline and online strategies, through online
advertisement and community forums40,61,65,82.
Finally, there were two major approaches regarding the mobile
phones in the trial: 36 studies (52.2%) provided participants with
study devices after randomisation, while 31 (44.9%) adopted a
bring your own device approach, downloading the app on the
participant’s smartphone. Only two studies adopted a mixed
strategy, opting to install the app on a loaned phone if the
participant was incompatible with the software version35,87. Key
study characteristics are summarised in Table 1, while a per-study
overview of selected study characteristics can be found in
Supplementary Table 1.
App design and development considerations. Five development
factors were analysed comparatively across all studies. Based on
the study conducted by Adu and colleagues24, we considered the
following factors: (i) supporting behavioural theory, (ii) user
involvement in the design, (iii) healthcare professional (HCP)
involvement in the design, (iv) data security and privacy
considerations, (v) pilot testing, which includes all forms of
interaction with target users to enhance the usability, acceptability
and reliability of the app before its complete testing (full details in
Supplementary Table 2).
Regarding health behavioural theories, only a minority of the
studies (n= 11, 15.9%) reported that the interventions were based
on theories and models of behaviour change and were beneficial
in developing apps35,42,43,47,52,57–59,61,73,90.
Concerning user involvement in app design, 21 studies (30.4%)
explicitly mentioned patient engagement strategies, incorporating
patient inputs in app design. While most simply cite an interactive
approach in close collaboration with intended users, a few specify
the process in greater detail. Ryan et al. based their formative work
on qualitative interviews of ten asthma patients and two research
staff to identify technological adjustments for improved solu-
tions88, while other publications included user requirements
through survey results93,99, iterative piloting95 or a consecutive
series of user studies during a 26-month development phase61. A
similar number also engaged HCPs in the app design phase (n=
18, 26.1%). While many studies adopted engagement strategies in
design involving both users and HCPs, there were a few
exceptions. Quinn et al.’s studies included only endocrinologists
and Certified Diabetes Educators in design30,31, while Yang et al.
adopted a Delphi Method with two consultation rounds involving
30 clinical and nursing experts50 and Greer et al. reported
extensive user testing by a team of clinical researchers43. On the
contrary, the Few Touch app was developed using focus groups,
interviews, feasibility testing and questionnaires over a 3-year
period with T2DM patients only53.
Data security and privacy information were documented by 33
of the studies (47.8%), mostly pertaining to secure data transfer
and storage from app to study servers, the minimisation of
medical/personal information stored on the mobile and obtained
through the app, and the password protection and encryption of
core data. A couple of studies mentioned compliance with the
Table 1. Key characteristics of included studies (n= 69).
Study characteristics n (%)
Disease area
Diabetes 29 (42.0%)
Cardiovascular diseases 13 (18.8%)












The Netherlands 5 (7.2%)
United Kingdom 5 (7.2%)
Finland 3 (4.3%)





Pilot RCT 12 (17.4%)
Cluster RCT 3 (4.3%)













Up to 1 month 6 (8.7%)
1–3 months 24 (34.8%)
4–6 months 26 (37.7%)









Study device approach 36 (52.2%)
Bring your own device approach 31 (44.9%)
Mixed approach 2 (2.9%)
aThe total number of included publications is equal to 74.
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Health Insurance Portability and Accountability Act30,31,38, while
Wayne et al. mentioned that the Connected Wellness Platform to
collect data exceeded Canadian privacy standards for software
carrying health information55. Only one study performed a
comprehensive risk analysis before the trial to ensure data privacy
and security53.
The incorporation of pilot testing into app development was
cited by 28 of the studies (40.6%), with eight additional trials
(11.6%) characterised as pilot RCTs themselves. Of those 28 studies,
the great majority reported observational single-arm studies
instrumental in assessing study feasibility and usability. Some
studies instead documented multiphase pilot testing: Vorrink et al.
reported three rounds of pilot testing initially starting with healthy
volunteers and later including COPD patients95, while Kearney
et al. developed and validated the advanced symptom manage-
ment system through a two-arm pilot study in Scotland with ten
patients receiving chemotherapy and a feasibility study to
evaluate the system’s acceptability on a convenience sample of
18 patients and nine HCPs98. Boer et al.’s Adaptive Computerised
COPD Exacerbation Self-management Support tool was validated
through a 3-month prospective observational study, but was
further optimised during the trial with a 2-week run-in period to
familiarise participants with the technology96. Finally, a few
studies that did not test apps specifically designed for research
purposes, but rather selected commercially available ones
adopted different forms of piloting, by identifying software with
the highest usability ratings by users or researchers adopting the
Mobile App Rating Scale39,40,84. The developmental factors
adopted are summarised in Table 2.
Features of the mHealth interventions. The interventions differed
significantly in content, level of HCP involvement and degree of
automation in decision support (Supplementary Table 3).
Regarding professional participation, 26 studies (37.7%)
excluded any in excess of that guaranteed to control patients
during routine follow-up visits. Among these, seven also
embedded a low technology-automation level in decision support:
three studies aimed at sharing information and increasing disease
awareness through the app58,82,97, while others either worked as
digital diaries allowing parameter recording under clinical super-
vision without direct intervention67,69, simulated e-therapy through
multimedia contents43 or delivered mindfulness training40. The
remaining 19 studies adopted more intensive automated technol-
ogy: four recorded participants’ medication adherence through
reminders39,63,84 or an artificial intelligence platform with dosing
instructions38; four others fostered improved physical activity
automatically selecting the appropriate intensity progression for
exercise regimens61,93,99 or providing feedbacks on trunk control79,
while the remaining 11 delivered automated advice or feedback
about the data entered in the app based on decision-support
systems or automated algorithms, with minimised involvement of
HCPs35,41,59,68,71,78,83,87,94,96,103.
On the other hand, 43 studies (62.3%) tested app interventions
including different forms of HCP involvement, which typically
engaged either clinicians or nurses. Among these, 23 did not pair
the HCP intervention with additional technological decision
support: one study facilitated therapy optimisation by providers
based on adherence overview37; two studies included HCP
involvement in classroom-based programmes33 or group ses-
sions42 as co-interventions to a lifestyle changing app with no
automated feedbacks; two others supported professional monitor-
ing of participants’ physical activity with the possibility of adjusting
goals95 or reinforcing adherence92; four enabled direct
patient–physician communication through forums or real-time
consultations44,46,47,70, while the remaining 14 transferred data to
dedicated professionals. A further distinction between this latter
group of 14 studies can be made between studies where the data
input was used by HCPs to provide personalised feedbacks during
visits or share recommendations through text messages with a
predefined frequency48,53,65,72,75,80,100,101, and those where data
transferred through the app continuously triggered study coordi-
nator intervention whenever the responses suggested a deterior-
ating health36,45,55,73,85,90.
The final 20 studies included both HCP involvement and
higher-intensity technology automation. Some of the app
interventions calculated and suggested optimal insulin doses
under general professional oversight and with facilitated
patient–physician communication51,56,64,66, while the remaining
provided automatic machine-based feedbacks as a first-level
support with the possibility for professionals to intervene if
warranted30,31,34,49,50,52,57,60,76,77,86,88,89,91,98,102.
Only five studies provided HCP with a mobile app coupled with
the patients’ ones. In Cingi et al.’s study, physicians could view all
patients’ inputs and respond to messages and broadcast multi-
media to participants through their app85. Similarly, in other
studies, a clinician app was associated with patient data34,45 or
enabled patient–physician communication44,55.
Regarding the behaviour change techniques (BCTs) adopted in
the studies104, the median number of BCT categories identified
was eight (mean 7.46, SD 3.02). Twenty interventions (29.0%)
included up to five BCTs, 37 had between five and ten BCTs, while
the remaining 12 (17.4%) had more than ten BCTs. The maximum
identified BCTs was 1467,68, while the most common individual
BCTs were: ‘Instruction on how to perform a behaviour’ (n= 49,
71,0%), ‘Feedback on outcomes of behaviour’ (n= 41, 59.4%),
‘Social support’ (n= 39, 56.5%), ‘Adding objects to the environ-
ment’ (n= 39, 56.5%), and ‘Self-monitoring of outcome(s) of
behaviour’ (n= 38, 55.1%) (Fig. 2). Of the 93 possible BCTs
identified in the taxonomy, 40 were used in at least one study and
14 in at least 14 (20%) studies.
Primary outcomes. Primary outcomes were explicitly identified in
56 studies (where a formal power calculation was performed) and
were classified based on the taxonomy for outcomes in clinical
research105. The types of primary outcome measures varied in
terms of core areas, although they most frequently pertained to
physiological and clinical outcomes (n= 29, 51.8% of the total
primary outcomes identified in the studies), followed by life
impact (n= 23, 41.1%), resource use (n= 3, 5.4%) and adverse
events (n= 1, 1.8%).
Regarding specific outcome domains, endocrine outcomes
were the most commonly reported, haemoglobin A1c levels
(n= 20), with only seven studies reporting significant differences
between groups at follow-up31,45,57,60,64,65,70. Among the remain-
ing studies, seven analysed the impact on physical functioning
and seven on delivery of care, both belonging to the life impact
domain. Regarding physical functioning, three studies evaluated
physical activity in terms of steps/day61,94,95, while two assessed
the impact on disease-specific self-care76,78 and two analysed the
change in respiratory function parameters through the 6-min
walking test93,99. Statistically significant improvements were
observed only in two studies61,78. With regard to care delivery,
six studies assessed the impact on medication adherence, through
Table 2. Developmental factors considered by the included studies
(n= 69).
Name Articles
Data security and privacy considerations 33 (47.8%)
Healthcare professional involvement in the design 18 (26.1%)
Pilot testing 28 (40.6%)
Supporting behavioural theory 11 (15.9%)
User involvement in the design 21 (30.4%)
M. Cucciniello et al.
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the administration of either a self-reported rating scale39,63,84,90, a
composite score83 or pill count36, while the remaining study
evaluated a cardiac rehabilitation programme80. Of these, five
studies demonstrated significant outcome improve-
ments39,63,80,83,84. All the reported primary outcome domains
classified by a core area and the statistical significance of the trial
results (with p value ≤0.05) are shown in Table 3, with additional
information in Supplementary Table 4.
Risk-of-bias assessment
Sixty-four (93%) studies presented an overall high risk of bias per
the Cochrane RoB 2 tool, whilst only five had a low risk for at least
four domains53,61,64,70,82. The main issue was the plausible
impossibility to blind study participants to the intervention,
together with potential deviations from the intended interven-
tions. The randomisation process and the selection of the reported
results were the domains showing the lowest bias risk. The
detailed, individual risk-of-bias analysis is provided in the
Supplementary information materials (Supplementary Fig. 1).
DISCUSSION
We systematically reviewed the randomised studies on the impact
of mhealth apps on four NCDs. We identified 69 studies (74
papers), published since 2008 from 24 countries, focusing on
diabetes (n= 29), CVDs (n= 13), chronic respiratory diseases (n=
13), cancer (n= 10) or combinations of these.
The mHealth app impact was assessed on a wide range of
primary outcomes. Per Dodd et al.’s taxonomy105, they most
frequently pertained to endocrine, cardiac or respiratory clinical
outcomes (n= 27, e.g. glycated haemoglobin and systolic blood
pressure), but also physical, emotional or cognitive functioning
(n= 11), care delivery (n= 7, e.g. medication adherence) and
global quality of life (n= 5). Although a quantitative synthesis was
not possible in this review due to the broad study aims and the
subsequent heterogeneity of the studies, we noted inconclusive
significance for many of them across chronic diseases. Statistically
significant, improved primary outcomes were reported in 26 stu-
dies (eight on endocrine outcomes, five on delivery of care
outcomes and three on cardiac outcomes, among others). These
results confirm the widespread concerns in the scientific literature
about the inability to couple the abundant production of mHealth
apps with adequate vetting processes to generate evidence for
their adoption106–108.
This review focused on two main cornerstones that help explain
the inadequacy of current peer-reviewed randomised studies of
mHealth apps and could be leveraged to improve future ones.
On one side, there are important considerations related to app
development, before the actual use in clinical studies. Our review
evaluated several developmental factors for possible adoption in
the design stage, all of which were inadequately recorded in the
majority of the studies.
Despite the criticality of data security and privacy issues, often
unaddressed with health apps109,110, only 33 studies documented
these aspects, even if preliminarily, in the trial report. Similarly,
only about a third of them reported user and HCP engagement
during the app design, through basic or more articulated (e.g.
Delphi process) strategies. Although our findings show some
improvements, vis à vis a previous review on diabetes self-
management apps24, more effort is needed to assign end-users a
pivotal role in app development through the incorporation of
their needs, expectations and experiences111. Furthermore, only
28 (45.9%) of the non-pilot RCT studies mentioned previous pilot
Fig. 2 BCT components adopted. Behaviour Change Techniques components and related clusters included in the selected studies (n= 69).
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testing of the intervention, which seems a missed opportunity to
prove a new intervention’s viability, manage its risk and identify
any deficiencies before substantial resource commitment. Finally,
few interventions (11, 15.9%) were grounded in behavioural
change theory. This shortcoming is currently a key missing
element for digital health tools to achieve sustained behaviour
change112 and could be related to software developers over-
looking important components for robust development and
evaluation113.
These critical steps in the app development process gain further
relevance considering that few mHealth solutions, among those
investigated in RCTs, progress to wide availability in routine
practice and major stores114, thus emphasising the paradox of
wide adoption of apps untested in clinical research, while clinically
investigated apps rarely scale up to real-world adoption.
As for HCP involvement, this review found 43 studies (62.3%)
with additional human-led components. The support or encour-
agement provided to the patient by someone, whether it is
directed at praising or rewarding behaviour or supporting self-
management could decisively impact the intervention. A previous
meta-analysis identified that, compared with diabetes apps with
low-frequency HCP feedback, those with high-frequency feedback
had a significant effect14. In the present review, studies involving
additional human-led components showed no higher likelihood of
a positive effect on outcomes for individuals in the
intervention arm.
In addition, app-based interventions can differ greatly in their
content and in the way they induce behaviour change. A median
of eight BCTs was tapped by each mHealth intervention, with
significant variability among them (SD 3.03). In apps containing
gamification strategies, which share significant overlap with health
BCTs and draw upon leader boards, prizes and rewards to motivate
individuals115, the median rises to 14 BCTs with consistent
inclusion of the ‘reward and threat’ category (81% apps)116.
Gamification is indeed a significant factor to acknowledge in the
development of mHealth apps for its promise to drive user
behaviour and increase engagement through game elements, and
ad hoc models have been proposed to support designers of
gamified, condition-oriented solutions117. However, the adoption
of gaming components was infrequent in the apps for chronic
NCDs in this review, with only 12 (17.4%) studies implementing
‘reward and threat’ techniques. The most common behaviour
change categories were instead ‘Feedback and monitoring’ (91%)
and ‘Shaping knowledge’ (72%). High prevalence of self-regulatory
techniques and, to a lower extent, prompts such as alerts and
reminders is coherent with previous studies118,119, although these
adopted an earlier 26-category taxonomy version120 and specifi-
cally aimed at promoting physical activity. A striking difference
from earlier reviews is the frequent incorporation of the BCT
‘Adding objects to the environment’, highlighting the ambivalence
between the adoption of personal and study devices in interven-
tion delivery. When an ad hoc device was provided after
randomisation, an extra object was added in the environment to
support the desired behaviour, and the related BCT was hence
recorded. Lack of awareness and research on specific combinations
of BCTs additionally emphasises the interventions’ poor grounding
in behaviour change theories.
Our findings highlight further methodological issues concerning
app testing.
A recent review of study protocols available via clinicaltrials.gov
examined the clinical evidence underlying digital health interven-
tions, highlighting the studies’ relatively low quality, small size and
limited likelihood of being significantly powered to demonstrate
treatment effects compared to drugs and traditional medical
devices, which mandate stricter regulatory guidelines on safety
and efficacy121. Although we considered published peer-reviewed
reports of interventional studies and not study protocols, our
results agree with the previous contribution: relatively short
follow-ups—only 13 studies followed up >6 months—and median
sample size of 94 patients, with several studies adopting
convenience sampling and others not reaching the expected
enrolment level or inadequately accounting for drop-out rates in
their sample size calculations. Furthermore, 28 were pilot RCTs in
need of subsequent investigation122. Also, formal risk-of-bias
assessment performed according to standard tools revealed a
high risk of bias for the majority of RCTs, highlighting the inability
of both currently published studies and available assessment
metrics to keep up with the specific methodological challenges of
mobile apps.
These results should be assessed considering the ongoing
literature debate on the evaluation of digital health interventions
and mHealth apps. While some reject digital exceptionalism and
accept RCTs as the golden standard123, others think that digital
technologies cannot be held to the same standards as new drugs/
devices124 and support the adoption of more agile, yet equally
robust, methodologies125. Given the distinguishing characteristics
of mHealth apps126, designs other than parallel-group RCTs have
been proposed. These include the multiphase optimisation
Table 3. Primary outcome domains and statistical significance (α ≤ 0.05) of the included studies (n= 56).
Core area Outcome domain Positive results Neutral results Negative results
II. Clinical outcomes 3. Cardiac outcomes 3 0 0
5. Endocrine outcomes 7 13 0
9. General outcomes 1 0 0
14. Metabolism and nutrition outcomes 1 0 0
22. Respiratory, thoracic and mediastinal outcomes 0 4 0
III. Life impact 25. Physical functioning 2 5 0
28. Emotional functioning/wellbeing 2 1 0
29. Cognitive functioning 1 0 0
30. Global quality of life 2 3 0
32. Delivery of care 5 2 0
IV. Resource use 34. Economic 0 1 0
35. Hospital 0 1 0
27. Societal/care burden 1 0 0
V. Adverse events 38. Adverse events/effects 0 1 0
M. Cucciniello et al.
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strategy (MOST), the sequential multiple assignment randomised
trial (SMART) and the micro-randomised trial127–130. This also
seems to be the direction embraced by some regulatory bodies
such as—for instance—the Federal Institute for Drugs and Medical
Devices in Germany (Bundesinstitut für Arzneimittel und Medizin-
produkte, BfArM) that recognises the relevance of alternative
study designs and methods such as Pragmatic Clinical Trials,
SMART or MOST131.
Nonetheless, none of these was implemented in the peer-
reviewed studies identified, emphasising the preference for
parallel-group RCTs or checklists of quality criteria that show
significant variability and no clear method for their
development132.
The review results additionally light up the current debate: with
55% of the randomised studies showing neutral findings—i.e.
non-significant difference—it is legitimate to discuss whether
results could have differed with more robust development and
design of the underlying apps, implementation of agile study
designs or appropriate study characteristics of the RCT studies.
Limitations
There are several limitations of the current review. A meta-analysis
was impossible due to the heterogeneity of studies explored. Non-
English papers were excluded. We reviewed randomised studies
only, which allowed focusing on the theoretically more robust
evidence to assess the impact of mHealth apps in chronic disease
while excluding other potentially relevant evidence sources.
Furthermore, the taxonomy adopted for the BCT analysis was
not specifically developed for mHealth apps, inevitably entailing
authors’ judgement. Finally, the coding was based on the
information in the study report and related sources. Some of
the features may have been untracked, possibly underestimating
the number of BCTs tapped.
CONCLUSIONS
This systematic review sheds light on how design and develop-
ment processes, choice of outcomes and behavioural change
theory underpinning mHealth apps are fundamental in determin-
ing the value of digital interventions.
Furthermore, based on exploratory quantitative analyses of the
association between study characteristics and a positive statisti-
cally significant result, our study seems to suggest a relatively
lower success among apps for respiratory conditions (asthma,
COPD) compared to CVDs, oncology or diabetes. This finding must
be confirmed in future studies, but certainly highlights how the
evidence on effective or cost-effective apps is not generalisable
tout court across different health conditions. The widely adopted
concept of ‘equivalence’ used in medical devices regulation
systems must be carefully considered in the case of mHealth
apps133,134. Another interesting finding is the lower proportion of
positive studies among those with longer (≥6 months) follow-up.
This may signal issues with sustained adherence and engagement
with the intervention and calls for research intended to identify
strategies that maintain higher levels of engagement of end-users
and successful retention rate in the long run.
Finally, among four different outcome areas, life impact
outcomes seem to report more positive results compared to
clinical outcomes, resource use or adverse events. This finding
draws attention to the importance of the most appropriate
outcome selection in the evaluation of mobile app interventions.
However, especially in view of the recently adopted EU
Regulation of Medical Devices and the upcoming EU Regulation
on Health Technology Assessment135,136, follow-up research is
urgently needed to further explore these elements that deserve
deeper attention, confirm these initial hypotheses and to better
investigate the impact of BCTs on the effectiveness of
mHealth apps.
Developers, methodologists and trialists are encouraged to
carefully consider these additional elements when designing or
running clinical evaluations of apps, to elucidate whether trial
results reflect their true benefits or a biased estimate due to
unsuitable designs or suboptimal implementation of the
intervention.
Acknowledging the specific features of health apps (e.g. security
issues, continuous content and software updates, and the
impossibility of blinding participants and investigators)126 is
necessary to support policy-makers, providers and developers in
their large-scale evaluation and consistent and effective deploy-
ment for chronic disease management.
The COVID-19 pandemic may have favoured large-scale
adoption of digital tools137, but only through sustained and
appropriate evidence generation they will shape successful care
models and significantly contribute to CD management.
METHODS
Information sources
This systematic review was guided by the PRISMA statement and
checklist138.
A literature search strategy was developed using keywords and
MeSH (Medical Subject Headings) related to mHealth apps and
pertinent chronic diseases. The full search strategy was first
defined on Medline (Supplementary Note 1) and then adapted to
the other engines. The search was performed on Medline (OVID
interface), ScienceDirect, the Cochrane Library and Scopus, and
last updated on 23 November 2019. To ensure literature
saturation, we scanned the reference lists of the studies and
systematic reviews and meta-analyses initially retrieved by the
search or recently completed on PROSPERO and added additional
publications of interest to the review. The review was not
registered. A detailed protocol was prepared and circulated
among the project team.
Eligibility criteria
The search strategy targeted trials with a randomised design
involving individuals with one of the four main NCDs as identified
by the World Health Organisation—cardiovascular diseases,
cancers, chronic respiratory diseases and diabetes139—and the
use of a mobile health app, a small, self-contained software coded
for a specific purpose and usually optimised to be downloaded
and run on mobile phones and tablets140. In terms of study
design, we selected any type of randomised trials (parallel-group
trials, cluster-randomised trials and cross-over trials, and other
recent study designs specifically developed for digital technology).
Concerning the target population, no further restriction criteria
based on patient characteristics, such as age, gender, ethnicity or
employment status were applied. All possible comparators were
deemed relevant, including current standards of medical care as
well as other eHealth interventions, such as telephone follow-up,
text messaging or a simplified version of the app intervention. All
quantitively measured outcomes were included and classified
based on Dodd et al.’s taxonomy105. In terms of publication status,
only peer-reviewed journal articles published in English after 2008
(when the App Store and PlayStore were first opened) were
eligible. We excluded studies where the app was only used by
HCPs or that focused on feasibility only. Further details about all
inclusion and exclusion criteria are provided in Supplementary
Table 5.
M. Cucciniello et al.
7
Published in partnership with Seoul National University Bundang Hospital npj Digital Medicine (2021)   144 
Study selection
Studies identified via database searches were first screened by title
and abstract by two independent reviewers (F.P. and M.C.).
Duplicates were excluded and, in case of disagreement, a third
independent reviewer was consulted (R.T.). For studies meeting the
inclusion criteria, or when unclear, the full article was retrieved. The
same reviewers assessed the full-text papers to determine
inclusion based on the stated eligibility criteria. For studies
deemed ineligible for inclusion at the full-text analysis stage, the
reasons for exclusion were recorded. Cohen’s kappa was calculated
to determine the inter-rater agreement between the reviewers.
Data collection and extraction
We used a pre-piloted data extraction form elaborating the
CONSORT-EHEALTH checklist extension141 and the Cochrane Con-
sumers and Communication Review Group’s data extraction
template142. Information was extracted from each study on: (i) study
design and participant characteristics; (ii) app design and develop-
ment; (iii) features of the mHealth intervention, including embedded
BCTs104; (iv) types of outcome measures and reported results.
Risk-of-bias assessment
Since no official methodological standards are available for
empirical studies on mobile apps, we used the Revised Cochrane
risk-of-bias tool for randomised trials (RoB 2)143.
Assessment of risk of bias is regarded as an essential component
of systematic reviews on the effects of an intervention. An evaluation
of the risk of bias in each study included in the systematic review
documents potential flaws in the evidence summarised and
contributes to the certainty in the overall evidence. The RoB 2 tool
provides a framework for assessing the risk of bias in a single
estimate of an intervention effect reported from a randomised trial
for a specific outcome or endpoint. This revised Cochrane tool was
published in July 2019 and is structured into five different bias
domains (i.e. risk of bias arising from the randomisation process, risk
of bias due to deviations from the intended interventions (effect of
assignment to intervention/effect of adhering to intervention),
missing outcome data, risk of bias in the measurement of the
outcome, risk of bias in the selection of the reported result). The
assessment of each domain eventually leads to one of the following
three judgements: low risk, some concerns or high risk. An overall risk
of bias judgement, based on the five dimensions introduced before,
is given to judge the overall confidence in the result. We assessed the
treatment effect on the primary outcome or, when the primary
outcome was not mentioned explicitly or could not be identified
indirectly through sample size calculations, on the first outcome
reported in the results144. One co-author performed the quality
assessment of studies (F.P.), and a second co-author independently
double-checked the assessment (O.C.).
Data synthesis
Given the broad scope of the review, considerably high hetero-
geneity in terms of the type of NCDs, study characteristics,
developmental factors, intervention structure and outcomes
observed were anticipated. Therefore, the preferred approach to
summarising the data was through a narrative synthesis, tabulation
and descriptive analysis of all items extracted from the studies.
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